Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
NCT04805983
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
36
Enrollment
OTHER
Sponsor class
Conditions
Alzheimer Disease
Interventions
DRUG:
BMS-984923
Sponsor
Yale University
Collaborators
[object Object]